Novozymes A/S (VIE:NZYM)
Austria
· Delayed Price · Currency is EUR | Market Cap | 23.40B |
| Revenue (ttm) | 4.14B |
| Net Income (ttm) | 547.00M |
| Shares Out | n/a |
| EPS (ttm) | 1.91 |
| PE Ratio | 42.79 |
| Forward PE | 24.15 |
| Dividend | 4.55 (9.14%) |
| Ex-Dividend Date | Mar 24, 2026 |
| Volume | n/a |
| Average Volume | n/a |
| Open | 49.32 |
| Previous Close | 49.96 |
| Day's Range | 49.32 - 49.78 |
| 52-Week Range | 49.13 - 65.48 |
| Beta | n/a |
| RSI | 41.77 |
| Earnings Date | Feb 25, 2026 |
About Novozymes
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and early lie nutrition. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional lau... [Read more]
Financial Performance
In 2024, Novozymes's revenue was 3.83 billion, an increase of 59.58% compared to the previous year's 2.40 billion. Earnings were 305.80 million, a decrease of -24.66%.
Financial StatementsNews
Novozymes A/S (NVZMY) Q4 2025 Earnings Call Transcript
Novozymes A/S (NVZMY) Q4 2025 Earnings Call Transcript
Novozymes A/S (NVZMY) Q3 2025 Earnings Call Transcript
Novozymes A/S (OTCPK:NVZMY) Q3 2025 Earnings Call November 6, 2025 3:00 AM EST Company Participants Tobias Björklund - Head of Investor Relations Ester Baiget - President & CEO Rainer Lehmann - Execut...
Novonesis A/S (NVZMF) Q2 2025 Earnings Call Transcript
Novonesis A/S (OTCPK:NVZMF) Q2 2025 Earnings Conference Call August 21, 2025 3:00 AM ET Company Participants Anders Lund - Chief Operating Officer Andrew Taylor - Corporate Participant Claus Crone Fug...
Novonesis: Industry Leader With Defensive Characteristics And Solid Growth
Novonesis is a global market leader in enzymes and biosolutions, offering defensive growth and resilience across essential industries like food, agriculture, and household care. The company has delive...
Novonesis A/S (NVZMF) Q1 2025 Earnings Call Transcript
Novonesis A/S (OTCPK:NVZMF) Q1 2025 Earnings Conference Call May 8, 2025 3:00 AM ET Company Participants Tobias Björklund - Head, Investor Relations Ester Baiget - Chief Executive Officer Rainer Lehma...
Novonesis A/S (NVZMF) Q4 2024 Earnings Call Transcript
Novonesis A/S (OTCPK:NVZMF) Q4 2024 Earnings Conference Call February 26, 2025 3:00 AM ET Company Participants Tobias Cornelius Björklund - Head, Investor Relations Ester Baiget - Chief Executive Offi...
Top 3 global stocks poised for 40% gains by 2025
Goldman Sachs has a list of global stocks it expects will outperform in 2025. In particular, the investment bank is bullish on three names – Novozymes, Kawasaki Heavy Industries, and PetroChina.
Novonesis A/S (NVZMF) Q3 2024 Earnings Call Transcript
Novonesis A/S (OTCPK:NVZMF) Q3 2024 Earnings Conference Call November 7, 2024 3:00 AM ET Company Participants Tobias Cornelius Björklund - Head, Investor Relations Ester Baiget - Chief Executive Offic...
Novonesis: Underperformance In Price, But Now I'm Buying (Rating Upgrade)
Novonesis, formed from Chr. Hansen and Novozymes, shows promising growth but remains overvalued with a current P/E of 33x, down from 40x. Organic sales for 9M24 rose 9%, driven by volume and pricing, ...
Novozymes A/S (NVZMF) Q2 2024 Earnings Call Transcript
Novozymes A/S (OTCPK:NVZMF) Q2 2024 Results Conference Call August 28, 2024 3:00 AM ET Company Participants Tobias Björklund - Head of Investor Relations Ester Baiget - President & CEO Rainer Lehmann ...
Invitation to an extraordinary shareholders' meeting of Novozymes A/S
An extraordinary shareholders' meeting of Novozymes A/S will be held on Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark.
The Novozymes Report 2023
This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on January 29, 2024.
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024 Company announcement No.
Novozymes A/S (NVZMF) Q4 2023 Earnings Call Transcript
Novozymes A/S (NVZMF) Q4 2023 Earnings Call Transcript
Legacy Novozymes delivers solid last full-year results
Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last...
Completion of the combination between Novozymes and Chr. Hansen
January 29, 2024 – Company announcement no. 2 Please see attachment.
The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner
Today, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for b...
All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
January 26, 2024 – Company announcement no. 1 Please see attachment.
Novozymes CEO is confident its merger with Chr. Hansen will close in Q1
Novozymes CEO Ester Baiget discusses the Danish biotechnology company's planned combination with with fellow biotech firm Chr. Hansen.
Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted
December 20, 2023 Please see attachment. Contact information Investor Relations Disa Tuominen+45 6038 5826 dkditu@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com A...
Novozymes' updated financial calendar
Please read the full announcement in PDF Attachment 2023_61_Updated_financial_calendar
Novozymes and Chr. Hansen announce name of future combined company; Novonesis
Novozymes and Chr. Hansen have announced that the name of the future combined company will be ‘Novonesis'. Novonesis means ‘A new beginning' and derives from the Greek word ‘genesis'. The name reflect...
Update on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained
December 12, 2023 Please see attachment. Contact information Investor Relations Disa Tuominen+45 6038 5826 dkditu@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com A...
Exclusive: Novozymes, Chr. Hansen tie-up likely to win EU nod, sources say
Danish food ingredients and enzymes makers Novozymes and Chr. Hansen are expected to secure EU antitrust approval for their all-share $22 billion tie-up based on remedies offered to address competitio...
Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.
November 20, 2023 Please see attachment. Contact information Investor Relations Anders Mohr Christensen+45 2515 2364 dkamc@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-han...